3-((1R,3R)-1-(2,6-Difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-8-fluoro-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2,2-difluoropropan-1-ol

ID: ALA4873860

Chembl Id: CHEMBL4873860

PubChem CID: 121410623

Max Phase: Preclinical

Molecular Formula: C27H30F6N4O

Molecular Weight: 540.55

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  C[C@@H]1Cc2c([nH]c3c(F)cccc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO

Standard InChI:  InChI=1S/C27H30F6N4O/c1-15-8-19-18-4-2-5-20(29)24(18)35-25(19)26(37(15)13-27(32,33)14-38)23-21(30)9-16(10-22(23)31)34-17-11-36(12-17)7-3-6-28/h2,4-5,9-10,15,17,26,34-35,38H,3,6-8,11-14H2,1H3/t15-,26-/m1/s1

Standard InChI Key:  DGCYBRDAKZFTDA-PVPMGCCUSA-N

Alternative Forms

  1. Parent:

    ALA4873860

    ---

Associated Targets(Human)

ESR1 Tclin Estrogen receptor alpha (17718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MCF7 (126967 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 540.55Molecular Weight (Monoisotopic): 540.2324AlogP: 5.00#Rotatable Bonds: 9
Polar Surface Area: 54.53Molecular Species: NEUTRALHBA: 4HBD: 3
#RO5 Violations: 2HBA (Lipinski): 5HBD (Lipinski): 3#RO5 Violations (Lipinski): 2
CX Acidic pKa: 12.80CX Basic pKa: 7.15CX LogP: 4.25CX LogD: 4.06
Aromatic Rings: 3Heavy Atoms: 38QED Weighted: 0.33Np Likeness Score: -0.64

References

1. Liang J, Zbieg JR, Blake RA, Chang JH, Daly S, DiPasquale AG, Friedman LS, Gelzleichter T, Gill M, Giltnane JM, Goodacre S, Guan J, Hartman SJ, Ingalla ER, Kategaya L, Kiefer JR, Kleinheinz T, Labadie SS, Lai T, Li J, Liao J, Liu Z, Mody V, McLean N, Metcalfe C, Nannini MA, Oeh J, O'Rourke MG, Ortwine DF, Ran Y, Ray NC, Roussel F, Sambrone A, Sampath D, Schutt LK, Vinogradova M, Wai J, Wang T, Wertz IE, White JR, Yeap SK, Young A, Zhang B, Zheng X, Zhou W, Zhong Y, Wang X..  (2021)  GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.,  64  (16.0): [PMID:34251202] [10.1021/acs.jmedchem.1c00847]

Source